International Journal of Vaccine Theory, Practice, and Research最新文献

{"title":"Buying and Selling with the “Mark of the Beast”","authors":"John W. Oller, Jr.","doi":"10.56098/ijvtpr.v1i2.20","DOIUrl":"https://doi.org/10.56098/ijvtpr.v1i2.20","url":null,"abstract":"The document appended here — an “International Application Published Under the Patent Cooperation Treaty (PCT)” — falls among the many “unprecedented” events witnessed during COVID-19. It was filed June 20, 2019 with the World Intellectual Property Organization (WIPO) under the PCT and its international publication date was March 26, 2020. Some have already scorned the idea that the document appended as the final entry to IJVTPR 1(2) is at least a partial fulfillment of an apocalyptic prophecy concerning the age-old conflict between good and evil. But it is as real and as relevant to COVID-19 as the vaccines that were envisioned and practically in production before SARS-CoV-2 infected the first human in Wuhan. Now, with the burden of the economic shut-down settling upon the people of the planet, the prospect of pandemics more deadly than COVID-19, has made many fearful enough to forfeit their free will to technocrats ready to manage them like robots. The patent applied for is about the buying and selling of “human necessities”. It would authorize the patent holder to use every manner of surveillance of an individual’s bodily states, actions, and thoughts to make the buying and selling of necessary products and services, contingent upon certain “work”, such as receiving or refusing to receive certain vaccines or meeting other requirements set by the patent holder.","PeriodicalId":391540,"journal":{"name":"International Journal of Vaccine Theory, Practice, and Research","volume":"316 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124474605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plan B Public Health Infrastructure and Operations Oversight Reform for America","authors":"James Lyons-Weiler","doi":"10.56098/ijvtpr.v1i2.19","DOIUrl":"https://doi.org/10.56098/ijvtpr.v1i2.19","url":null,"abstract":"It’s not the public that needs more monitoring and oversight: it is the US regulatory agency of public health network and the pharmaceutical companies that run them. In this paper, I provide a blueprint for a bona fide public health infrastructure based on independence of freedom from corporatism.","PeriodicalId":391540,"journal":{"name":"International Journal of Vaccine Theory, Practice, and Research","volume":"205 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124615222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addendum to “HCG Found in Tetanus Vaccine”: Examination of Alleged “Ethical Concerns” Based on False Claims by Certain of Our Critics","authors":"J. Oller, Christopher A. Shaw, L. Tomljenovic, W. Ngare, S. Karanja, Jamie Ryan Pillette, F. Clement","doi":"10.56098/ijvtpr.v1i1.3","DOIUrl":"https://doi.org/10.56098/ijvtpr.v1i1.3","url":null,"abstract":"This updated addendum to “HCG Found in WHO Tetanus Vaccine in Kenya Raises Concern in the Developing World” (published October 28, 2017 by OALibJ) addresses arguments claiming to discredit it from John Broughall, a retired microbiologist, and from an unnamed person (or persons) going by the pseudonym “The Original Skeptical Raptor” (hereafter, “Raptor”). Our paper (Oller et al., 2017), hereinafter referred to as the “hCG-paper”, judging from the Web of Science and PubMed databases, was the first peer-reviewed scholarly work showing the scope of the WHO anti-fertility program focusing on “less developed countries” from 1972 to the present: (1) It examined official policy statements from the UN’s largest donor nation dating from 1975 about the perceived need for “far greater efforts at fertility control” especially in “less developed countries” (National Security Council, 1975, 2014). (2) It documented the stream of published research in that program directly or indirectly sponsored by the WHO. (3) It compared the stepped-up dosage schedule used by the WHO in the Kenya 2013-2015 vaccination campaign which was appropriate to their “birth-control” vaccine but radically different from any previously published schedule for ordinary tetanus vaccine. (4) It analyzed and documented the sources of laboratory data from accredited laboratories in Nairobi finding ?hCG in at least one-third of the samples of vaccine actually collected at the 2014 administration sites. (5) It revealed the convergence of all the foregoing sources of information supporting the charge of the Kenya Catholic Doctors Association leveled against the WHO (Kenya Catholic Doctors Association, 2014). In emails to OALibJ, Broughall claimed “ethical concerns” about the hCG-paper urging the publisher to retract it. Raptor said, “Open Access Library Journal . . . is a predatory journal” and the hCG-paper is a “pseudoscientific . . . outright lie” (The Original Skeptical Raptor, 2017).","PeriodicalId":391540,"journal":{"name":"International Journal of Vaccine Theory, Practice, and Research","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123903138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brave New World: Omens and Opportunities in the Age of COVID-19","authors":"J. Oller, C. Shaw","doi":"10.56098/ijvtpr.v1i1.2","DOIUrl":"https://doi.org/10.56098/ijvtpr.v1i1.2","url":null,"abstract":"In this inaugural issue of IJVTPR, the authors have focused on a variety of themes that are intended to highlight some of the ongoing controversies in the vaccine literature, controversies that have been made all the more acute by the emergence of COVID-19. With this pandemic have come societal disruptions that have caused governments around the globe to move rapidly to “state of exception” measures. It is at times such as this, that independent scholarly research is most urgently needed. The current issue is our opening salvo that attempts to bring rigorous independent and unbiased research to the subject of vaccine safety and analysis. The article by Shaw looks at how the process that has governed scientific review for centuries — peer review — has been corrupted in an attempt to sanitize the literature in order to remove studies that do not conform to a corporate line. It seems certain that in the new age of COVID-19, such measures will only increasingly harm and obscure honest science. The paper by Oller et al. follows up on the 2017 article about the apparent distribution of a World Health Organization anti-fertility vaccine represented as a prophylactic for maternal and neonatal tetanus. The article by David Lewis takes an important alternative look at potential etiological factors that might contribute to the rising prevalence of autism, factors that are not per se the direct result of vaccination but that involve some of the pathogens and components from that industry. Next, Sin Hang Lee takes an intensive critical look at the components in Gardasil9. It is a vaccine deploying gene-edited recombinant capsid L1 proteins converted to virus like particles to stimulate immunity against human papilloma viruses of types 6, 11, 16, 18, 31, 33, 45, 52, and 58. In theory it also requires one or more strong adjuvants to jump start the generation of antibodies against the various viruses. Because Lee’s paper addresses an application of gene editing research in vaccine development, it adumbrates our next issue in which we intend to address so-called “dual use” and “gain of function” research with potential pandemic pathogens preceding the present COVID-19 pandemic.","PeriodicalId":391540,"journal":{"name":"International Journal of Vaccine Theory, Practice, and Research","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114847441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Autism Biosolids Conundrum","authors":"David C. Lewis","doi":"10.56098/ijvtpr.v1i1.4","DOIUrl":"https://doi.org/10.56098/ijvtpr.v1i1.4","url":null,"abstract":"ABSTRACT \u0000 Before Congress passed the Clean Water Act of 1972, municipalities throughout the United States discharged hazardous municipal and industrial wastes directly into rivers and other waterways. Every chemical and biological agent linked to neurodevelopmental disorders, including those linked to “autism spectrum disorders” (ASDs), spilled into coastal waters and settled on the bottoms of the oceans. The solution to pollution was dilution. To comply with the Clean Water Act of 1972, President Carter created wastewater treatment plants throughout the United States to extract heavy metals and toxic organic chemicals from water and concentrate them in sewage sludges that were dumped offshore and buried in landfills. In 1988, Congress banned ocean dumping of sewage sludges because of their potential for causing vaccine-derived polio epidemics. Suddenly, high concentrations of every heavy metal, toxic organic chemical and vaccine-derived viruses linked to autism, including rubella and cytomegalovirus, had no place to go but land. The solution to pollution shifted from diluting pollutants in water to concentrating them on land at hundreds of thousands to millions of times higher concentrations, including on commercial farms that produce our nation’s food supplies. Now, all of the most dangerous pollutants regulated by EPA no longer require biomagnification up the food chain to harm public health. Promoted by EPA and the USDA as safe and environmentally beneficial, land application practices quickly spread worldwide. Here, the author relies largely, albeit not exclusively, on EPA’s own research to address the implications. As a whole, it indicates that the global shift that EPA’s 503 Sludge Rule created in the accumulation of pollutants from ocean sediments to populated land surfaces is causally related to sharp increases in the incidence of neurodevelopmental disorders worldwide. Autism in its severe infantile form is more or less at the center of this entire class of disorders that appears to have become epidemic beginning in late 1988. EPA dismissed controversial claims linking MMR vaccination to autism, but never addressed the role that widespread land application of sewage sludges (a.k.a. biosolids), which contain highly virulent strains of vaccine-derived measles, rubella and other viruses, may play in autism. Notwithstanding this glaring omission, the global shift that EPA policies on biosolids created in human exposures to complex mixtures of measles, rubella and other viruses derived from live vaccines, combined with high concentrations of potentially every heavy metal and chemical pollutant linked to autism, could explain sharp increases in the incidences of autism and other ASDs that began in 1988.","PeriodicalId":391540,"journal":{"name":"International Journal of Vaccine Theory, Practice, and Research","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123850993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toll-like Receptor 9 Agonists in HPV Vaccine Gardasil9","authors":"Si-Hyeong Lee","doi":"10.56098/ijvtpr.v1i1.5","DOIUrl":"https://doi.org/10.56098/ijvtpr.v1i1.5","url":null,"abstract":"Gardasil9 is a recombinant human papillomavirus (HPV) 9-valent vaccine, containing purified major capsid L1 protein of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 re-assembled into virus-like particles (VLPs) as the active ingredients. Since the antigens are purified recombinant proteins, in theory Gardasil9 needs a potent adjuvant to generate high and sustained levels of antibodies. Historically, amorphous aluminum hydroxyphosphate sulfate (AAHS), listed as the adjuvant for Gardasil9, was known to require one or more Toll-like receptor agonists, such as the phospholipids in the recombinant hepatitis B vaccine, Recombivax HB®. However, there are no phospholipids in the purified HPV L1 proteins or in Gardasil9. But the Food and Drug Administration (FDA) reports that Gardasil4 does contain recombinant HPV L1-specific DNA fragments, and they may serve as Toll-like receptor 9 agonists in Gardasil9. The author has tested 5 samples of Gardasil9 from 4 manufacturing lots by PCR amplification with a set of degenerate primers followed by heminested PCR or by another 5 sets of non-degenerate nested PCR primers in an attempt to detect all 9 vaccine-relevant HPV type-specific L1 gene DNAs bound to AAHS in the vaccine. Sanger sequencing confirmed the presence of HPV 18, 11, 16 and 6 L1 gene DNA bound to insoluble AAHS nanoparticles, but they were unevenly distributed even within the same vaccine sample. Also, these fragments were at least partially in non-B conformations. Since no L1 gene DNA of HPV 31, 33, 45, 52, and 58 was amplified by the commonly used degenerate PCR primers, the results suggest that these may all be in non-B conformations or may have been removed as contaminants by a purification protocol. Further research is warranted to standardize the HPV DNA fragments in Gardasil which are known to be potent Toll-like receptor 9 agonists.","PeriodicalId":391540,"journal":{"name":"International Journal of Vaccine Theory, Practice, and Research","volume":"395 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123717462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weaponizing the Peer Review System","authors":"C. Shaw","doi":"10.56098/ijvtpr.v1i1.1","DOIUrl":"https://doi.org/10.56098/ijvtpr.v1i1.1","url":null,"abstract":"The long-revered “peer review” process, as it is currently being applied in the health sciences, is increasingly controlled by commercial interests that are in too many instances using it as a tool forcing technical publications in prestige journals and books toward certain outcomes favorable to those interests. The “peer review” process has in the last two decades especially, increasingly become a process to serve the interests of the manufacturers and promoters of drugs and medicines. Although it was conceived as a way to ensure quality in academic and scientific publications it has increasingly, especially in the health sciences, taken on a commercial aspect with power, momentum, and governmental support that enables it to be used to against unwanted outcomes that threaten the bottom line of those commercial interests. This paper examines the process as it was intended to be used and contrasts its good purposes for uses to which some bad actors are presently perverting it. The practical limits of the problem and remedies to staunch the bleeding, so to speak, are plainly laid out. There is no intention to give legal advice, but merely to examine recent experience looking toward what can be done to preserve the good and valid uses of the imperfect process of peer review.","PeriodicalId":391540,"journal":{"name":"International Journal of Vaccine Theory, Practice, and Research","volume":"17 4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125788212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}